Evaluation of cell-free DNA approaches for multi-cancer early detection
Arash Jamshidi(SUNY Upstate Medical University), Charles Swanton(The Francis Crick Institute), Onur Sakarya(University of California, Santa Barbara), Peter Freese(Menlo School), Kathryn N. Kurtzman(Menlo School), David D. Thiel(WinnMed), Roger Jiang(Menlo School), Archana Shenoy(Menlo School), Siddhartha Bagaria(Menlo School), Daniel Civello(Menlo School), Dong Zhao(Hebei Medical University), Minetta C. Liu(Mayo Clinic), Alan H. Bryce(Mayo Clinic Hospital), Vasiliki Demas(Menlo School), Kristan K. Steffen(Menlo School), Earl Hubbell, Kristi McIntyre(Texas Health Dallas), Oliver Venn(Centre for Human Genetics), Robert Calef(Menlo School), Mikkael A. Sekeres(University of Miami), Virgil Nicula(Menlo School), Konstantin Davydov(Menlo School), Alexander M. Aravanis(Illumina (United States)), Alexander P. Fields(Apple (Israel)), Seyedmehdi Shojaee(Menlo School), John F. Beausang(Menlo School), Qin‐Wen Liu(Menlo School), Donald A. Berry(Berry & Associates (United States)), Hamed Amini(Menlo School), Collin Melton(Menlo School), Joshua Newman(Menlo School), Craig Betts(Menlo School), Tom C. Chien(Menlo School), Nathan Hunkapiller(Menlo School), Saniya Fayzullina(Menlo School), Nan Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Susan Tang(Menlo School), Eric Scott(Menlo School), Eric T. Fung(Menlo School), Donald Richards(Texas Oncology), Chenlu Hou(Menlo School), Byoungsok Jung(Menlo School), Samuel Gross(Menlo School), Mohan K. Tummala(Mercy Clinic Cancer and Hematology), Allen Lee Cohn(Rocky Mountain Cancer Centers), Michael V. Seiden(Emergency University), Timothy J. Yeatman(University of South Florida), Eric A. Klein(Meta (United States))
Cited by 311
Related Papers
Large-Scale Identification, Mapping, and Genotyping of Single-Nucleotide Polymorphisms in the Human Genome
|Science|1998|2.2k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k